<DOC>
	<DOCNO>NCT02307227</DOCNO>
	<brief_summary>Prospective , monoinstitutional , phase II study . Patients HER 2 positive locally advanced breast cancer treat 3 initial cycle ( 12 week ) trastuzumab plus paclitaxel respond 12 week surgical resection , patient HER2 negative breast carcinoma treat 4 cycle ( 12 week ) epirubicin taxotere . If respond 4 cycle ( 12 week ) . Patients progress treated depend physician 's patient 's preference</brief_summary>
	<brief_title>Phase II Study With Trastuzumab + Paclitaxel Locally Advanced HER2+ Tumors Epirubicin + Taxotere HER2- Tumors</brief_title>
	<detailed_description>Primary Objective : determine pathological complete response ( pCR ) correlation immune response . Secondary Objectives : - determine progression free survival ( PFS ) overall survival ( OS ) ; - evaluate safety treatment particular attention cardiac safety . Inclusion Criteria : - Histologically prove breast carcinoma evaluate HER 2 status immune status - Locally advanced carcinoma ( UICC stage II-III ) - Age &lt; 70 year - measurable lesion - ECOG Performance Status 0-2 - Life expectancy &gt; 3 month - Adequate bone marrow hepatic function - Creatinine Clearance &gt; 40 ml/min - Written inform consent - Patients must accessible treatment follow Exclusion criterion : - Prior chemotherapy hormonal treatment - Brain metastasis . - Past current history neoplasm curatively treat . - Concurrent treatment experimental drug . - Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % - History significant neurological psychiatric disorder . Treatment HER2 positive ( defined 3+ Herceptest FISH/CISH positive ) Herceptin 4mg/kg first time , 2 mg/kg weekly concomitant paclitaxel 80 mg/mq weekly ( one cycle correspond 4 week ) 12 week ( 3 cycle ) . Clinical instrumental evaluation , respond patient continue additional 12 week ( total 6 cycle ) , surgical excision HER2 negative : Epirubicin 90 mg/mq docetaxel 75 mg/mq every 3 week 4 cycle . Clinical instrumental evaluation , respond patient continue additional 12 week ( total 8 cycle ) , surgical excision . Main Parameters Activity : - Complete Remission ( CR ) : complete disappearance previously detectable disease period least 28 day , new lesion . - Partial Remission ( PR ) : 30 % reduction long diameter target lesion , new lesion . - Stable Disease ( SD ) : le 30 % reduction le 20 % increase long diameter target lesion new lesion . - Progressive Disease ( PD ) : increase size 20 % least one lesion previously document disease . Or appearance disease site . - Progression Free Survival ( PFS ) measure first day treatment first observation disease progression death due cause last date patient know progression free alive . - Overall Survival ( OS ) compute time first day treatment date death last date patient know alive . Main Parameters Safety : - Adverse event , laboratory parameter . - All toxicity grade use NCI common toxicity criterion ( Appendix II ) . Cardiac event ( CHF ) grade accord NYHA Study procedure : - At Baseline : - Complete medical history , ECOG PS , physical examination ( include neurological examination , height , weight , ) , - ECG - Left ventricular ejection fraction evaluation ( LVEF , evaluate echocardiography ) . - Blood chemistry ( fast blood sugar , transaminase , serum alkaline phosphatase , total bilirubin , total protein , albumin , creatinine , PT , f√¨brinogen ) - Complete blood count differential - Calculated Creatinine Clearance/24 h - Chest X- ray - Abdomen computer tomography ( CT ) ultrasound - Bone scan X-ray ( appropriate ) - Written inform consent . - During Treatment - Every Cycle : - Blood chemistry - Complete blood count differential - Toxicity evaluation - Physical examination - During Treatment - Every 12 week ( 3-4 cycle ) : - Breast ultrasound - Surgical medical evaluation - Left ventricular ejection fraction evaluation ( LVEF ) evaluate echocardiography - ECOG PS - Before surgery : - Mammography , Ultrasound Magnetic resonance - Long term Follow - Every 3 month first 2 year , every 6 month year 3-5 yearly - Survival Statistical Considerations : The aim phase II clinical trial detect 20 % improvement pCR ( i.e. , 25 % 54 % ) . Simon 's method use calculate sample size . Accrual 46 patient plan consider 80 % power detect 20 % difference ( two-sided type I error =0.05 ) . The Chi-square test Fisher 's exact test use qualitative parameter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically prove breast carcinoma evaluate HER 2 status immune status Locally advance carcinoma ( UICC stage IIIII ) Age &lt; 70 year measurable lesion ECOG Performance Status 02 Life expectancy &gt; 3 month Adequate bone marrow hepatic function Creatinine Clearance &gt; 40 ml/min Written inform consent Patients must accessible treatment follow . Prior chemotherapy hormonal treatment Brain metastasis . Past current history neoplasm curatively treat . Concurrent treatment experimental drug . Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % History significant neurological psychiatric disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>